Shalini Sharp - Jun 4, 2021 Form 4 Insider Report for Organon & Co. (OGN)

Role
Director
Signature
/s/ Faye C. Brown, as Attorney-in-Fact for Shalini Sharp
Stock symbol
OGN
Transactions as of
Jun 4, 2021
Transactions value $
$326,649
Form type
4
Date filed
6/8/2021, 08:31 PM
Previous filing
Jun 7, 2021
Next filing
Jan 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OGN Common Stock 2 Jun 4, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Phantom Stock Award $327K +9.06K $36.05 9.06K Jun 4, 2021 Common Stock 9.06K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired in a pro rata distribution by Merck & Co., Inc. ("Merck") of shares of Organon & Co. ("Organon") in connection with the separation of Organon from Merck (the "Separation").
F2 1-for-1
F3 Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,512 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases.